Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax by Patel, Seema et al.
Published online 2 August 2008 Nucleic Acids Research, 2008, Vol. 36, No. 16 5139–5151
doi:10.1093/nar/gkn490
Molecular interactions of ASPP1 and ASPP2
with the p53 protein family and the apoptotic
promoters PUMA and Bax
Seema Patel
1, Roger George
2, Flavia Autore
3, Franca Fraternali
3,
John E. Ladbury
2 and Penka V. Nikolova
1,*
1Department of Biochemistry and Pharmaceutical Science Division, School of Biomedical and Health Sciences,
King’s College London, Franklin-Wilkins Building, 150 Stamford St., London SE1 9NH,
2Division of Structural and
Molecular Biology, University College London, Darwin Building, Gower Street, London WC1E 6BT and
3Randall
Division of Cell and Molecular Biophysics, New Hunt House, School of Biomedical and Health Sciences, King’s
College London, London SE1 1UL, UK
Received June 9, 2008; Revised July 15, 2008; Accepted July 16, 2008
ABSTRACT
The apoptosis stimulating p53 proteins, ASPP1 and
ASPP2, are the first two common activators of the
p53 protein family that selectively enable the latter to
regulate specific apoptotic target genes, which facil-
itates yes yet unknown mechanisms for discrimi-
nation between cell cycle arrest and apoptosis. To
better understand the interplay between ASPP- and
p53-family of proteins we investigated the molecular
interactions between them using biochemical meth-
ods and structure-based homology modelling. The
data demonstrate that: (i) the binding of ASPP1 and
ASPP2 to p53, p63 and p73 is direct; (ii) the C-termini
of ASPP1 and ASPP2 interact with the DNA-binding
domains of p53 protein family with dissociation con-
stants, Kd, in the lower micro-molar range; (iii) the
stoichiometry of binding is 1:1; (iv) the DNA-binding
domains of p53 family members are sufficient for
these protein–protein interactions; (v) EMSA titra-
tions revealed that while tri-complex formation
between ASPPs, p53 family of proteins and PUMA/
Bax is mutually exclusive, ASPP2 (but not ASPP1)
formed a complex with PUMA (but not Bax) and dis-
placed p53 and p73. The structure-based homology
modelling revealed subtle differences between
ASPP2 and ASPP1 and together with the experimen-
tal data provide novel mechanistic insights.
INTRODUCTION
The p53 protein is one of the best known tumour suppres-
sor proteins because of the high frequency of its mutations
in a wide range of human cancers. The protein exerts its
tumour suppressor function either by triggering cell cycle
arrest or apoptosis. Precisely, which of the two alternative
pathways are needed to enable p53 to block tumour devel-
opment and how exactly the cells decide which pathway
to choose is not well understood. Induction of apoptosis
is the most evolutionary conserved function of p53 and
key for tumour suppression (1). The p53 protein is known
to mediate apoptosis by transactivating many genes in res-
ponse to DNA damage or cellular stress. However, p53
can also mediate apoptosis by independent pathways (2).
Transcriptionally inactive p53 mutants can induce apo-
ptosis in certain tumour cells (3). Although the intrinsic
mechanism is unknown, protein–protein interactions
between p53 and other cellular proteins may be involved
in transcription-independent apoptosis by p53. The dis-
covery of the phylogenetically older tumour suppressor
p53 family members, p73 and p63, brought excitement
and controversy over whether and how they cooperate
with p53 in tumour suppression (4–6). It raised the expec-
tations that a cross talk between these family members
might exist to govern the cell cycle arrest and apoptosis
in response to stress. Although p73 and p63 are rarely
mutated in cancer, studies suggest that p73 and p63 may
function independently and/or in concert with p53 to elicit
cell death (7–9).
As proteins, the p53 family share remarkable similarity
at the structural and functional levels, but also have dis-
tinct, non-overlapping functions. Each family member
functions as a sequence-speciﬁc transcription factor and
is induced by diﬀerent types of stress stimuli including
DNA damage. All three proteins are implicated in cell
death pathways. The p73 and p63 proteins are more simi-
lar to each other than to p53. They share >60% amino
acid sequence identity with the p53 DNA-binding domain
*To whom correspondence should be addressed. Tel: +44 207 848 4276; Fax: +44 207 848 4500; Email: penka.nikolova@kcl.ac.uk
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.and can activate the expression of p53-responsive elements
(p53RE). However, the proteins have also uniquely spe-
cialized functions and are involved in diﬀerent biological
processes, which suggest that they are not redundant (10).
Urist and Prives (11) proposed that p73 and p63 might
be required for stable association of p53 with subset of
its target promoters and hence forming large assembly
of transcriptional complexes containing the three proteins.
Finally, some promoters might be selectivity regulated by
the interaction of p53 with increasing number of proteins
that act as transcriptional co-factors by discriminating
selectively and stabilizing p53 (12,13). Evidence in support
of the latter view came when the so-called apoptosis
stimulating p53 proteins (ASPPs) were reported to interact
speciﬁcally and to enhance the apoptotic function of p53,
but not that of the cell cycle arrest (14). The ASPP
proteins achieve this by binding speciﬁcally to the DNA-
binding domain of p53 and activating transcription
selectively from p53 responsive pro-apoptotic genes
(i.e. Bax, PUMA and PIG3) over growth arrest genes
(i.e. p21, mdm2). It was suggested that the ASPP–p53
complex acts at gene promoters, with ASPP’s subtly alter-
ing the ability of the p53 protein to bind to DNA. Since
the DNA-binding domain is the most conserved domain
among all p53 family members, it was expected that
ASPP1 and ASPP2 could also interact with p73 and p63
to induce apoptosis independently of p53. Using RNA
interference to remove endogenous p73 and p63 revealed
that the p53-independent apoptotic functions of ASPP1
and ASPP2 were mediated by p73 and p63, making
ASPP1 and ASPP2 the ﬁrst common activators of the
p53 family of proteins (15).
The ASPP family of proteins consists of three proteins,
ASPP1, ASPP2 and iASPP. Their names are derived
from the fact that they are ankyrin repeat, SH3 domain
and proline-rich domain containing proteins. In terms of
their function they are apoptosis stimulating proteins
of p53. ASPP2 was identiﬁed originally as 53BP2 (p53-
binding protein 2), which is now recognized to be the
C-terminal 528 amino acids of ASPP2 (14,16). Due to its
inhibitory eﬀect on apoptosis, the third family member
was called iASPP. ASPP1 and ASPP2 share about 49%
sequence homology with the highest identity observed at
the N- and C-terminal ends, but it is not known if they
have overlapping or redundant functions. Although the
precise molecular mechanism by which ASPPs selectively
stimulate DNA-binding remains unclear, both p73 and
p63, like the ASPP family of proteins, were reported to
be required for p53-independent apoptosis (1,13).
The interaction between the DNA-binding domain
of the p53 protein and the ankyrin and SH3 domains
of 53BP2 was shown by the 2.2A ˚ structure between frag-
ments of the proteins (17). The structure revealed that the
SH3 domain binds to the L3 loop of p53 and the fourth
ankyrin repeat binds to the L2 loop of p53 DNA-binding
domain. It is now well established that L2 and L3 of p53
are evolutionary conserved and that many of the p53
cancer-associated mutations are located at these sites.
Not surprisingly, the six most frequent p53 mutations in
cancer, known as ‘hot spots’, disrupt 53BP2 binding
in vitro. Importantly, the 53BP2-binding site overlaps the
site of p53 DNA binding (17–19). Recently, the structures
of the N-terminal 83 amino acid of ASPP2 as well as the
C-terminal fragment of iASPP (a.a. 608–828) were solved
(20,21). It was also reported that the ASPP2 proline-rich
domain is natively unfolded (22). While the role of the
ASPP proteins in cancer remains to be fully elucidated it
has been observed that loss of expression of ASPP1 and
ASPP2 had been detected in breast cancers (14). Loss of
expression of ASPP’s is known to partially inhibit the
ability of chemotherapeutic drugs to cause apoptosis,
apparently by blocking p53’s apoptosis-inducing function.
A p53-derived apoptotic peptide was shown to derepress
p73 to exert tumour regression in vivo regardless of p53
status (4) and a small molecule RETRA has been used
to suppress mutant p53-bearing cancer cells via a p73-
dependent pathway (6). These studies provide a proof
of principle strategy to directly and selectively utilize p73
for therapeutic beneﬁts.
Here, we investigate the structural–molecular mecha-
nism of interaction of the DNA-binding domains of
the p53 family of proteins, (p53, p63 and p73) with the
C-terminal domains of ASPP1 and ASPP2. We provide
direct, quantitative information about the intrinsic
nature of these protein–protein interactions using biophy-
sical and biochemical methods. To shed further light on
how these proteins might cooperate in apoptosis, we
assembled protein–DNA complexes between a select set
of apoptotic promoters known to interact with all three
members of p53 protein family and titrated them with
either ASPP1 or ASPP2. Using EMSA we further exam-
ined the possibility of tri-complex formation between p53
(p63, p73), PUMA or Bax and ASPP1 or 2. Our ﬁndings
conﬁrmed that: (i) C-terminal regions of ASPP1 and
ASPP2 directly interact with the DNA-binding domains
of p53, p63 and p73 with similar aﬃnity; (ii) the binding of
the C-terminal region of ASPP2 (and ASPP1) and PUMA
(or BAX) to the DNA-binding domains of p53, p63 and
p73 is mutually exclusive; (iii) the C-terminal region of
ASPP2 but not that of ASPP1 interacts directly with
both p53, p73 or PUMA but not Bax, forming an
ASPP2–PUMA complex; (iv) ﬁnally, using molecular
modelling and structure-based alignment we mapped
and compared the residues involved in the protein–protein
interactions. The data are discussed in the light of possible
use of p73 (and p63) as activators of apoptosis. The impli-
cations are that the latter could be exploited in cancer
treatment, in cases where tumours are expressing mutant
p53, or where p53 is not present.
MATERIALS AND METHODS
Molecular cloning
The corresponding fragments for the C-terminal (four
ankyrin repeats and an SH3 domain) constructs of inter-
ests containing a.a. 863–1090 and 902–1128, for ASPP1
and ASPP2, respectively were subcloned into a pRSET-
derived plasmid containing 6xHis tags at its N-terminal
end. The subcloning of the DNA-binding domains of
p53 family of proteins, namely, p53 DBD (a.a. 94–312),
p63 DBD (a.a. 154–365) and p73 DBD (a.a. 104–333)
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viously (23,24). The p53, p63 and p73 constructs do not
have tags.
Protein expression and proteinpurification
Cell cultures of Escherichia coli C41 (DE3) were grown
in 2 TY medium supplemented with ampicillin at 378C
(200–250r.p.m.) to an OD600 0.6–0.8. The temperature
was then reduced to 16–228C before overnight induc-
tion with 0.5mM IPTG. Cells were harvested by centri-
fugation at 48C and then lysed in BugBuster Protein
Extraction Reagent supplemented with Benzonase
Nuclease (Novagen, Nottingham, UK), with EDTA-free
protease inhibitor tablets (Roche, Burgess Hill, UK) and
4mM DTT. The protein samples were spun down at
13000r.p.m. for 20min at 48C. The puriﬁcation of the
DNA-binding domains of p53, p63 and p73 were per-
formed as reported previously (23,25,26). For ASPP1
and ASPP2, the soluble fraction was puriﬁed using
batch puriﬁcation with Ni-NTA resin (Qiagen, Crawley,
UK) (50mM NaPi, 300mM NaCl, 20mM imidazole,
1mM DTT and 10% glycerol). The supernatant obtained
after the BugBuster extraction procedure was poured into
a glass beaker with the Ni beads and incubated at 48Cb y
shaking for 45min. The suspension was then spun at
4000r.p.m. for 10min at 48C and the supernatant dis-
carded. The beads were washed with 10 column volumes
of binding buﬀer as above and the supernatant discarded.
The bound protein was eluted from the beads using ﬁve
column volumes of elution buﬀer (5mM NaPi, 300mM
NaCl, 300mM imidazole, 1mM DTT and 10% glycerol)
by centrifuging at 4000r.p.m. for 5min at 48C.
Circular dichroism
Proteins were subjected to the circular dichroism (CD)
scans at concentrations 0.2mg/ml in 10mM NaPi,
100mM NaCl, 4mM DTE buﬀer. Samples were ﬁltered
with 0.2mm ﬁlters (Whatman). The CD studies were per-
formed using an Applied Photophysics Chirascan spectro-
polarimeter. Far-UV spectra were recorded in the region
260–190nm, respectively using 0.5mm cell path length,
1nm bandwidth, 0.5nm scan speed, 3s time-per-point.
The temperature was controlled using Melcor’s thermo-
electric temperature controller. Data are represented in
ellipticity as a function of the wavelength (nm) and calcu-
lated according to Schmid (27).
Isothermal titration calorimetry
The buﬀers for each protein used were 50mM NaPi,
200–300mM NaCl, 1–5mM DTT and 0–10% glycerol
and ﬁltered via a 0.2mm ﬁlter (Whatman). The protein
concentrations used for ASPP1:p53 were 11mM:200mM,
ASPP1:p63 were 4.5:80mM and ASPP1:p73 were
7:100mM; ASPP2:p53 were 15:300mM, ASPP2:p63 were
10:260mM and ASPP2:p73 were 25:560mM. All experi-
ments were carried out using the VP-(Isothermal titration
calorimetry) ITC Micro-Calorimeter with the following
parameters: 20 injections of 15ml with 240s spacing, refer-
ence power 14 pCal/s, stirring speed 300 and at 108C.
Controls were performed by titrating each protein
sample used at a higher concentration in the syringe,
into the sample cell ﬁlled with buﬀer alone.
Experimental data were ﬁtted assuming a single binding
site (Microcal VPITC user guide).
Analytical gelfiltration
Analytical gel ﬁltration was performed in 50mM NaPi,
pH 7.2, 200mM NaCl, 5mM DTT using a Superdex
200 (10/300) column (GE Healthcare, Little Chalfont,
UK). The proteins were injected at a concentration of
40mM with an injection volume of 100ml and the milli-
absorbance units (mAu) at 280nm were recorded.
Complexes were incubated at 228C for 25min.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) were carried
out with all p53 family of proteins and 50-ﬂuorescein-
labelled 30-mer dsDNA promoters of Bax and PUMA
using 0.7% agarose gel and TB buﬀer at a constant cur-
rent of 60V at 48C. The DNA concentrations were kept
constant, while the p53, p63 and p73 protein concentra-
tions were increased. The protein concentration at which
most (or all) of the DNA was shifted was then selected for
the titration with the ASPP proteins. The ﬂuorescein tag
enabled sensitive detection under UV light. Protein–DNA
complexes were incubated on ice for 20min. To investigate
the possibility of tri-complex formation and or displace-
ment of the DNA from the protein–DNA complexes, the
ASPP proteins were then titrated into these complexes and
incubated for further 30min at 48C before loading onto
the gel. In addition, we tested if ASPP1 and ASPP2
would be able to shift the same DNA promoters under
the experimental conditions. The oligonucleotides used in
the EMSA were annealed by heating at 958C for 5min
followed by cooling to 48C overnight. The following
sequences were used:
Bax (forward): GGGCTCACAAGTTAGAGACAAG
CCTGGGCG
Bax (reverse): CGCCCAGGCTTGTCTCTAACTTGT
GAGCCC
PUMA (forward): CGCGCCTGCAAGTCCTGACTT
GTCCGCGGC
PUMA (reverse): GCCGCGGACAAGTCAGGACTT
GCAGGCGCG
Modelling
The model structures of p63, p73 and ASPP1
were obtained by homology modelling from the crystal
structure of p53 in complex with ASPP2 (PDB accession
number 1ycs) (17). All the modelled sequences share at
least 60% sequence identity with the corresponding tem-
plate, therefore ensuring reliable homology models (28).
Sequence alignments were generated by using the T-coﬀee
method (29). Three-dimensional models were generated
using the MODELLER package, which can generate a
large number of models and performs an optimization
of the generated models with respect to a deﬁned objective
function. This software has been used for wide-scale struc-
ture modelling of genomes (30). The selected models were
chosen on the basis of the objective function’s score.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5141To reﬁne the models, energy minimizations were per-
formed with the GROMACS package (31) using the
GROMOS96 force ﬁeld (32). Images were produced
with visual molecular dynamics (VMD) 1.8.5 (33). The
complexes of the p53 family members and ASPP1 were
constructed by analogy to the complex of p53 with
ASPP2 in the 1ycs coordinate ﬁle. To characterize the
interaction surfaces, the program POPScomp was used
(34,35) to detect the residues that are buried upon complex
formation. POPScomp calculates the solvent accessible
surface area (SASA, in A ˚ 2) of each residue before and
after the formation of the complex. The structural align-
ment was performed with the program aliss (Jens
Kleinjung, personal communication). Electrostatic sur-
faces were calculated by the use of the program
PYMOL (36) with the implemented subroutine surface
APBS (37).
RESULTS
Determination of theoligomerization status ofthe
proteins using gelfiltration
Prior to investigating the possible direct interaction
between the DNA-binding domains of the p53 family of
proteins, p53 (a.a. 94–312) DBD, p63 DBD (a.a. 154–365)
and p73 DBD (104–333) and the C-termini of ASPP1 (a.a.
863–1091) and ASPP2 (a.a. 902–1128) (containing four
ankyrin repeats and an SH3 domain) (Figure 1A and B)
we expressed the corresponding fragments of the proteins
in E. coli and examined the oligomeric and folding states
of the proteins. For these experiments, we used the
DNA-binding regions of the p53 family of proteins,
which mapped to the well-characterized p53 DNA-bind-
ing domain (a.a. 94–312). Gel ﬁltration studies conﬁrmed
that all the constructs were monomeric (Figure 2A) with
apparent experimental molecular masses being in good
agreement with the theoretically calculated values.
Far UV CD spectra ofASPP1 and ASPP2proteins
to test iftheproteins arefolded
Far-UV (190–260nm) CD spectra of ASPP1 and ASPP2
were recorded to assess the folding state of the proteins
(Figure 2B). The spectra were recorded at 208C. As
depicted in Figure 2B, the spectra for both ASPP1 and
ASPP2at 208C showed overlapping scans with minima
at 208 and 222nm which are characteristic of folded
proteins.
DoASPP1andASPP2binddirectlytop53familyofproteins?
Having established that the proteins of interest are mono-
mers in solution and folded at 208C, we tested if there
is direct interaction between the ASPP proteins and the
corresponding DNA-binding domains of the p53 family of
proteins using ITC and analytical gel ﬁltration. Diﬀerent
ratios were tested to establish the strength of the interac-
tions. The interaction between ASPP2 and p53 DBD was
used as a control since it has been reported that the two
proteins interact (16,17,19). Our ITC experiments pro-
vide for the ﬁrst time quantitative data and show that
both ASPP1 (Figure 3A–C) and ASPP2 (Figure 3D–F)
interact directly with all three p53 family of proteins,
namely p53, p63 and p73. The Kd values for all the inter-
actions are similar and are in the lower micro-molar range
(between 0.5 and 5mM) (Table 1). These values are in
excellent agreement with the recently published Kd value
of binding for p53 DBD to 53BP2 (namely ASPP2),
with virtually identical constructs (19). ITC provides an
Figure 1. Schematic diagram of the domains of (A) the p53 family of
proteins, indicating the TA, transactivation domain; DBD, DNA-bind-
ing domain; TET, tetramerization domain and SAM, Sterile Alpha
Motif domain. (B) The ASPP family of proteins, indicating the b-
Grasp domain; Pro, proline rich domain; Ank, four ankyrin repeat
domains and SH3, domain.
Figure 2. (A) Gel ﬁltration elution proﬁles of all proteins on Superdex 75
26/60 HP column. The elution proﬁles for p53 DBD (blue), p63 DBD
(green), p73 DBD (cyan), ASPP1 (black) and ASPP2 (red). (B) Far UV
CD spectra of ASPP1 and ASPP2. The CD spectra for ASPP1 (black)
and ASPP2 (red) were recorded in the region 190–260nm on a Chirascan
spectrometer at 208C and using a 0.5mm cell path length.
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concentrations of the interacting components in titration
are known. We performed several repeat experiments to
try to ensure that the stoichiometry evaluation was cor-
rect. In some experiments evidence of aggregation of the
complex was noted, however in these experiments the stoi-
chiometry was aﬀected and hence could be ignored (38).
Furthermore, the data illustrate that the DNA-binding
domains of the p53, p63 and p73 are suﬃcient for the
interaction with the C-terminal domains of ASPP1 and
ASPP2, consisting of the four ankyrin repeats and the
SH3 domain. A direct interaction between these pro-
teins was also conﬁrmed by analytical size exclusion
chromatography. Figure 4A–C shows the relevant
Figure 3. ITC analysis of the protein–protein binding interactions between the C-terminal region of ASPP1 (A–C) and ASPP2 (D–F) with DNA-
binding domains of p53, p63 and p73, respectively.
Table 1. ITC analysis of the protein–protein interactions between ASPP1 and ASPP2 with the p53 family of proteins
Protein–protein complex Ka (M
 1) Kd (mM) N value H (kcalmol
 1)T S (kcalmol
 1) G (kcalmol
 1)
ASPP1+p53 DBD 1.9 10
6 0.5 1.1  1.4 6.7  8.1
ASPP1+p63 DBD 1.3 10
6 0.8 1.0  3.7 4.3  8.0
ASPP1+p73 DBD 1.2 10
6 0.8 1.0  5.4 2.5  7.9
ASPP2+p53 DBD 2.0 10
5 5.0 1.0  1.9 4.9  6.8
ASPP2+p63 DBD 4.0 10
5 2.5 0.9  2.0 5.3  7.3
ASPP2+p73 DBD 4.7 10
5 2.1 0.9  0.3 7.0  7.3
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with p53, p63 and p73.
Howmight theASPP1 and ASPP2 proteins selectively
stimulate theapoptotic function ofthe p53family
ofproteins and hence actas commonactivators?
To gain further understanding of the molecular mech-
anism of interaction between the ASPP1 and ASPP2
and the p53 family of proteins we tested the following
hypothesis: (i) is there a tri-molecular complex forma-
tion between ASPP1 and/or ASPP2, the p53 family of
proteins and the pro-apoptotic response elements (RE)?;
(ii) are ASPP1 and ASPP2 proteins capable of displac-
ing (competing oﬀ) p53, p63 and or p73 from the
pro-apoptotic RE known to preferentially bind to all
three p53 family of proteins?; (iii) are the ASPP1 and
ASPP2 proteins common activators of p53, p63 and
p73? To investigate the above questions, we carried out
EMSA studies with puriﬁed recombinant proteins and
30-mer dsDNA promoters of Bax and PUMA as model
pro-apoptotic REs known to interact with all three p53
family of proteins (Figures 5 and 6).
The EMSA data show that all p53 family of proteins,
namely p53, p63 and p73, can interact with the pro-
apoptotic promoters tested forming high molecular mass
multimeric protein–DNA complexes (Supplementary
Figure 1A–F). However, upon titration of ASPP2 the
pro-apoptotic promoters are displaced from the p53–
(p63– and p73–) DNA complexes (Figure 5A–F), respec-
tively. Interestingly, under similar experimental con-
ditions, ASPP1 does not seem to displace DNA from
the preformed protein–DNA complexes, likely due to
the weaker interactions of ASPP1 with the respective
p53 protein members (Figure 6A–F and Supplementary
Figure 2E and F), respectively. Furthermore, ASPP1 is
able to enhance the DNA-binding activity of p53, p63
and p73 on Bax promoter only. Our results demon-
strate that the p53, p63 and p73 cannot bind simulta-
neously to both ligands, namely ASPP1 (ASPP2) and
pro-apoptotic promoters. Therefore, the tri-complexes
are not formed with the constructs tested. Unexpectedly,
we observed that when we titrated high enough concentra-
tions of ASPP2 into the p53–PUMA (or –Bax) complex
(Figure 5A, D and Supplementary Figure 2A, D) or
p73–PUMA complex (Figure 5C and Supplementary
Figure 2C), the ASPP2 protein also formed ASPP2–
DNA complexes, which migrate below the p53– or
p73–DNA complexes, due to the lower molecular mass.
It is known that p53 DBD and p73 DBD form tetrameric
protein–DNA complexes (23). However, we did not
observe such tendency with ASPP1 (Figure 6B, E) or
with ASPP2 and p63 (Figure 5B, E and Supplementary
Figure 2B) under the experimental conditions tested.
To investigate if the ASPP2 interaction with DNA
was speciﬁc, we performed a control experiment where
instead of PUMA or BAX we used a random DNA of
the same length. No binding was observed as shown in the
EMSA depicted in the Supplement Figure 2G.
Furthermore, upon titrating back p53 or p73, the pre-
formed ASPP2–DNA complex was stripped from the
DNA to form the p53– or p73–DNA complexes
(Supplementary Figure 2A, C, D).
ModellingtheinteractionsofASPP1orASPP2andp73(p63)
using structure-based alignment
To map the protein–protein binding surfaces of p73
and p63 with ASPP2, we used the X-ray structure of the
p53–53BP2 complex as well as sequence alignment to
build the models (17). Based on this structure the corre-
sponding interacting residues in p63 and p73 (Figure 7B
and C) were mapped onto the ASPP2 binding
surface (Figure 7H) and shown in Table 2. Similarly, we
modelled the structure of ASPP1 (Figure 7G) in complex
with the p53 family of proteins (Figure 7A–C and
Figure 4. Protein–protein interaction between ASPP2 and p53 (A), p63
(B) and p73 (C) monitored by analytical gel ﬁltration (Superdex 200
10/300). p53, p63 and p73 are shown in blue, ASPP2 in green and the
protein–protein complexes (1:1) in red.
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family members a number of diﬀerences can be observed
between the interacting residues of p53 and those in p63/
p73. The tumour suppressor p53 contains more polar,
positively charged residues than p63/p73, namely His
178, Arg 181, Ser 183 and Met 243 in p53, which are
Asn 246/196, Leu 249/199, Arg 251/201 and Val 313/263
in p63/p73 (highlighted in Table 2). However, these sub-
stitutions are unlikely to aﬀect the protein–protein inter-
actions. The structural alignment of ASPP1 and ASPP2
reveals that Met 1021, Tyr 1023, Met 1026 and Asp 1093
in ASPP2, are Ser 983, Ile 985, Ile 988 and Ser 1055 in
Figure 5. EMSA results after the model protein–DNA complexes were titrated with increasing concentrations of ASPP2, namely, p53–PUMA (A),
p63–PUMA (B), p73–PUMA (C), p53–Bax (D), p63–Bax (E) and p73–Bax (F).
Nucleic Acids Research, 2008, Vol. 36, No. 16 5145ASPP1, respectively, (Table 2). The majority of these sub-
stitutions are with amino acids of similar chemical proper-
ties so the binding interactions in which they participate
remain the same. The analysis of the residues at the inter-
face between the p53-family members and ASPP1/2
(Figure 8) showed that in the complexes with ASPP2 the
residue Asp 1093 interacts with the two most frequently
mutated p53 residues in cancer, Arg 248 and Arg 273.
These are the only two residues that are involved in the
interaction of both p53 with ASPP2 and p53 with DNA.
Figure 6. EMSA results after the model protein–DNA complexes were titrated with increasing concentrations of ASPP1, namely, p53–PUMA (A),
p63–PUMA (B), p73–PUMA (C), p53–Bax (D), p63–Bax (E) and p73–Bax (F).
5146 Nucleic Acids Research, 2008, Vol. 36, No. 16Figure 7. Structure-based homology modelling showing protein–protein complexes of p53 (A and D); p63 (B and E) and p73 (C and F) with ASPP1
(G, I, K) and ASPP2 (H, J, L). The models for p63, p73 and ASPP1 were based on the structure 1ycs. The ribbon representation of the proteins
(A–C, G, H) have been colour coded as follows: p53 (cyan), p63 (orange), p73 (red), ASPP1 (yellow), ASPP2 (green), zinc atom (purple),
DNA-binding site (light purple), hydrophobic residues (white), polar residues (green), negative residues (red) and positive residues (blue).
Comparison of the electrostatic potential of the p53, p63, p73 (D–F) and ASPP1 (I and K) and ASPP2 (J and L). The potential ranges from the
negative value  6kT (red) to the positive value +6kT (blue). Panels (K) and (L) depict ASPP1 and ASPP2 rotated 1808 relative to panels (I) and (J),
respectively.
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with the uncharged Ser 1055 in ASPP1 results therefore in
a loss of this functional interaction (Figure 8C). In addi-
tion, the distance between the OH-group of the Ser 1055
side-chain and the NH3
+ group of the side chains of the
two arginines is >4.3A ˚ .
With regards to p53 cancer-associated DNA contact
mutants, R248Q (W) and R273H, the following observa-
tions could be made based on the structure-based homol-
ogy models. In general, the p53 region of 248 is in close
proximity with some bulky residues in ASPP2, creating
steric hindrance (i.e. the tryptophan at position 1097 in
ASPP2). Speciﬁcally, when R248 in p53 is mutated to
tryptophan there would be a steric clash with the glutamic
acid (a.a.1094) in ASPP2. The arginine substitution
to glutamine (Q) in p53 creates a weaker interaction
with the aspartic acid (D) at position 1093 in ASPP2.
There is a stretch of negative residues (a.a. 1090–1096)
EDEDEIE in ASPP2 facing the R248 in p53. Therefore
a charged residue such as Arg in position 248 seems to
favour the binding with ASPP2. For R273 it has been
reported that this amino acid residue is located at the
edge of the ASPP2 binding interface (17). The model
proposed here (Figure 8C) suggests that the substitution
of arginine to histidine at position 273 would disturb the
interaction with aspartic acid 1093 in ASPP2 and there-
fore weaken the binding.
The structure-based sequence alignment between p53,
p63 and p73 shows that the Arg 248 and Arg 273 are
conserved. Hence, the same conclusions could apply to
p63 and p73. The electrostatic surfaces of the p53 family
members, namely p53, p63, p73 (Figure 7D–F), respec-
tively, are very similar since they are all mainly positively
charged but p63 and p73 show a relatively more positive
surface than p53 around the DNA-binding site. This could
account for the diﬀerent selectivity within the p53 family
of proteins for p53 RE. The electrostatic p53-binding sur-
faces for ASPP1 and ASPP2 show an overall negative
charge (Figure 7I and J), but a positive charge on the
opposite side (Figure 7K and L). It is reasonable to
assume that the ASPP–DNA interactions observed in
the EMSA occur on the positive interface. The ‘back
view’ of ASPP2 appears to have a more positive surface
area than ASPP1, which could provide further evidence
for our observation that ASPP2 displaces the DNA more
readily than ASPP1.
DISCUSSION
To shed further light on how ASPP1 and ASPP2 might
stimulate apoptosis we investigated the intrinsic nature of
the interactions between the ASPP1 and ASPP2 and the
p53 family of proteins, namely p53, p63 and p73, using
biochemical and biophysical methods with puriﬁed pro-
teins. We have probed the mechanism of these interactions
by using Bax and PUMA as model apoptotic promoters.
We ﬁrst show that ASPP1 and ASPP2 directly interact
with p53, p63 and p73 and that the DNA-binding domains
of the p53 family of proteins are suﬃcient for the interac-
tion with the ASPPs. Our data based on the equilibrium
binding constants obtained by ITC also show that the
interaction between the C-terminal domains of ASPP1
and ASPP2 to p53 DBD, p63 DBD and p73 DBD are
very similar and are in the lower micro molar range.
This is to be expected given the high amino acid identity
in the DNA-binding domains between the p53 family
members (about 60%) and C-termini of ASPP1 and
ASPP2 (80%).
Evidence for possible interaction of ASPP2, which was
known as 53BP2, with p53 (but not with mutant p53) was
Table 2. Buried SASA for the protein–protein complexes of ASPP2 and ASPP1 with the p53 family of proteins based on 1ycs [Gorina and Pavletich,
(17)]. The most signiﬁcant diﬀerences between ASPP1 and ASPP2 and between the p53 family members are shown in bold
Residue p53 DBD p63 DBD p73 DBD
Residue iSASA Residue iSASA Residue iSASA
A ˚ 2 A ˚ 2 A ˚ 2
ASPP2
TYR 1023 HIS 178 121.6 ASN 246 91.0 ASN 196 47.2
SER 1024 ARG 181 62.5 HIS 247 16.0 LEU 199 31.0
MET 1026 SER 183 48.3 GLU 252 33.2 ARG 201 153.7
GLN 1071 SER 241 32.9 SER 311 28.8 SER 261 34.0
ASN 1072 MET 243 101.4 VAL 313 18.0 VAL 263 73.6
GLU 1094 ASN 247 40.2 ASN 317 22.8 ASN 267 43.7
GLU 1096 ARG 248 153.6 ARG 318 164.6 ARG 268 154.4
TRP 1097 ARG 280 29.2 ARG 350 53.7 ARG 300 29.5
ASPP1
ILE 985 HIS 178 110.6 ASN 246 71.4 ASN 196 49.4
SER 986 ARG 181 58.3 LEU 249 54.2 LEU 199 47.3
ILE 988 SER 183 49.8 ARG 251 63.2 ARG 201 143.2
GLN 1033 SER 241 32.5 SER 311 28.8 SER 261 31.7
ASN 1034 MET 243 102.0 VAL 313 54.5 VAL 263 77.1
GLU 1056 ASN 247 39.6 ASN 317 49.0 ASN 267 41.7
GLU 1058 ARG 248 151.9 ARG 318 147.7 ARG 268 149.5
TRP 1059 ARG 280 29.0 ARG 350 24.5 ARG 300 22.5
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report showed that p53 cannot bind simultaneously to the
C-terminal fragment of ASPP2 and to a DNA containing
the p53 consensus binding sequence. However, no refer-
ence was made with respect to ASPP2 or ASPP1 binding
to DNA. The interaction between ASPP2 and p53 protein
was conﬁrmed when the X-ray structure of the complex
between the p53 tumour suppressor DNA binding domain
and the ankyrin and SH3 domains of the 53BP2 was
solved (17). The structure revealed that the 53BP2-binding
interface to p53 protein overlapped with the DNA-binding
site. This observation provided the framework for under-
standing why the most frequently mutated p53 residues in
human cancers called ‘hot spots’ failed to bind to ASPP2
as well as to DNA (17). Samuels-Lev et al. (14) identiﬁed
that 53BP2 was the C-terminal fragment of a much larger
protein, which was termed ASPP2, and identiﬁed its
homologue ASPP1. Furthermore, it was shown that
both ASPP1 and ASPP2 can stimulate the apoptotic func-
tion not only of p53 but also that of the p53 homologous
proteins p63 and p73 (15). However, the molecular
mechanism of stimulation of apoptosis by ASPP1 and
ASPP2 remains unknown.
To further investigate the mechanism of enhancement
of apoptosis by ASPP1 and ASPP2, we carried out in vitro
DNA-binding studies using two model apoptotic pro-
moters, Bax and PUMA. Our EMSA results show that
all proteins, p53 DBD, p63 DBD and p73 DBD, bind to
both Bax and PUMA speciﬁcally although with diﬀerent
aﬃnity. Having established the conditions at which
most of the DNA was shifted into a complex with the
corresponding proteins we then titrated increasing
amounts of ASPP1 and or ASPP2 into the pre-formed
protein–DNA complexes to test the possibility of tri-
complex formation. Our data revealed that by titrating
increasing amounts of ASPP2, the apoptotic promoter,
Bax, was displaced from the preformed p53–, p63– and
p73–DNA complexes. These observations suggest that
the binding between ASPP2 and p53 (or p63 or p73)
might be stronger than that between p53– (or p63– or
p73–) Bax complexes. Indeed, our Kd values for the
ASPP2–p53 (or -p63 or -p73) interactions are 0.5–5mM.
The Kd value of p53 with Bax has been reported to be
48mM (19), which is about 10-fold lower aﬃnity than
the protein–protein interactions for ASPP2 and the p53
family of proteins.
Figure 8. Superimposition of the p53–DNA complex (1tsr) onto the p53–ASPP2 protein–protein complex (1ycs). The overlaid structures are shown
in (A). Structure (A) rotated at 1808 is shown in (B). The colour coding is as follows: p53 DBD (cyan), DNA (pink), ASPP2 (green). (C) Close-up
view of the interface of p53 and ASPP2 side-chains (with the model of ASPP1 overlaid) are shown in liquorice representation, Arg 248, Arg 273 and
Asp 1093 are coloured according to atoms type; Ser 1055 (in ASPP1) is displayed in orange and hydrogen bonds in black.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5149Similar observations were reported recently for p53 and
53BP2 with PIG3 and Bax (19). The authors showed
that some key p53 mutants such as R273H can bind to
53BP2 with low micro molar range aﬃnity and conﬁrmed
that binding between the p53 and 53BP2, and DNA is
mutually exclusive since 53BP2 competes oﬀ the DNA
(pro-apoptotic RE of p53) (19). Robinson et al. (21)
reported the Kd’s for iASPP and ASPP2 with p53 family
of proteins using a solid phase binding assay (rather than
equilibrium studies which were used here) and a shorter
construct of ASPP2 (a.a. 905–1128). The Kd values are
signiﬁcantly diﬀerent than those observed here and that
of p53 DBD and ASPP2 by Tidow et al. (19). Surprisingly,
we observed ASPP2 binding to PUMA when high enough
concentrations were titrated into p53– or p73–PUMA
complexes. Furthermore, upon challenging the preformed
ASPP2–PUMA complex with relatively small excess of
p53 or p73, we observed displacement of ASPP2 from
the complex, resulting in p53– or p73–PUMA complexes.
This suggests that p53 and p73 have higher aﬃnity for
PUMA than ASPP2 for PUMA.
Our studies with ASPP1 and p53 family of proteins
whilst showing a similar trend as the data with ASPP2,
suggest that higher concentrations of ASPP1 are needed
to displace the DNA from the preformed protein–DNA
complexes. It is plausible that ASPP1–p53, –p63 and –p73
complexes have diﬀerent DNA-binding abilities towards
diﬀerent promoters i.e PUMA versus Bax. We carried out
structure-based alignment to probe the interface between
the ASPP2, p63 and p73 based on the X-ray structure of
the complex between ASPP2 and p53. In addition, we
built models between ASPP1 and p53, p63 and p73. The
models provide further evidence that the binding of the
DNA and ASPP1 or ASPP2 to p53 or p63 or p73 is
mutually exclusive due to the overlapping binding inter-
face, which cannot accommodate tri-complex formation
(as supported by our structure-based homology modelling
depicted in Figures 7A and B and 8A and B). The models
provide further evidence in support of the potential diﬀer-
ences in the DNA-binding abilities between ASPP1 and 2
as well as the diﬀerences in the displacement of the p53–,
p63– and p73–DNA complexes.
CONCLUSIONS
Several models were postulated to explain how a cell
might choose between cell cycle arrest and cell death.
One of those models (the selective binding model) pro-
posed that the ASPP1 and ASPP2 proteins might act as
co-factors and hence might alter the p53 binding speci-
ﬁcity and selectivity facilitating their binding to the
apoptotic promoters (13). Alternatively, co-factors such
as Haematopoietic zinc ﬁnger (HZF), which is induced
by p53 and binds to its DNA-binding domain, might
result in preferential transactivation of cell cycle arrest
promoters.
However, our results taken together with reports by
others ruled out the possibility of tri-complex formation
as a possible mechanism of stimulation of apoptosis by
ASPP1 and ASPP2. Could ASPP2 and/or ASPP1 binding
speciﬁcally to proapoptotic promoters provide a clue for
their function as coactivators of p53 protein family?
Further structural and molecular studies are needed to
probe deeper into the mechanism and function of these
proteins.
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